Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
Open Access
- 22 February 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (14) , 18424-18439
Abstract
Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerKeywords
This publication has 61 references indexed in Scilit:
- Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)Molecular and Clinical Oncology, 2013
- Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomasBritish Journal of Cancer, 2012
- Resistance to EGFR-Targeted Therapy: A Family AffairCancer Cell, 2011
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinaseProceedings of the National Academy of Sciences, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- IQGAPs in cancer: A family of scaffold proteins underlying tumorigenesisFEBS Letters, 2009
- A helix scaffold for the assembly of active protein kinasesProceedings of the National Academy of Sciences, 2008
- Mechanism of Activation and Inhibition of the HER4/ErbB4 KinaseStructure, 2008
- Surface comparison of active and inactive protein kinases identifies a conserved activation mechanismProceedings of the National Academy of Sciences, 2006
- Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cellsOncogene, 2000